<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1363">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774305</url>
  </required_header>
  <id_info>
    <org_study_id>3-2012-0142</org_study_id>
    <nct_id>NCT01774305</nct_id>
  </id_info>
  <brief_title>Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy</brief_title>
  <official_title>Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coughing during emergence from general anaesthesia may lead to dangerous effects including
      laryngospasm, detrimental haemodynamic changes. Post-thyroidectomy bleeding occurs in 1-4%
      of patients, and severe coughing may cause bleeding. Dexmedetomidine, a potent Î±
      adrenoreceptor agonist, is theoretically appropriate for reducing airway and haemodynamic
      reflexes during emergence from anaesthesia.

      In this study, we investigated whether intravenous single-dose dexmedetomidine at the end of
      surgery reduces coughing during extubation after thyroidectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Coughing Grade</measure>
    <time_frame>from the time of eye opening to 5 min after extubation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The coughing incidence and severity will be measured at extubation. Especially from the time of eye opening to 5 min after extubation. The coughing grade was assessed by the following cough grading system: Grade 0, no cough or single, mild cough at extubation; Grade 1, multiple, not sustained cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergence Time</measure>
    <time_frame>from sevoflurane discontinuation, up to the time of eye opening (estimated time : from 5 min to 10 min)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The emergence time will be recorded as the time from sevoflurane discontinuation to eye opening on command.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Coughing</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.</description>
    <arm_group_label>saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status 1 or 2 patients patients scheduled for thyroidectomy

        Exclusion Criteria:

          -  Severe cardiovascular disease history of motion sickness active status of upper
             respiratory infection allergy to dexmedetomidine patients who cannot understand
             Korean
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gangnam severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>December 22, 2012</firstreceived_date>
  <firstreceived_results_date>June 17, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jeong Soo Lee</investigator_full_name>
    <investigator_title>Yonsei university college of medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment period : Sep.2012. ~ Jan. 2013 types of location : medical clinic.</recruitment_details>
      <pre_assignment_details>there was no specific pre-assignment details.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A patient in group Dexmedetomidine was not completed this study due to changed surgery plan. (Intubated time prolonged more than 3 hours)</population>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="141"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="141"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.3" spread="10.4"/>
                <measurement group_id="B2" value="45.6" spread="12.3"/>
                <measurement group_id="B3" value="45.5" spread="11.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>smoking</title>
          <description>It has been known that smoking history is related to coughing.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>smoking</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>non-smoking</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="111"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coughing Grade</title>
        <description>The coughing incidence and severity will be measured at extubation. Especially from the time of eye opening to 5 min after extubation. The coughing grade was assessed by the following cough grading system: Grade 0, no cough or single, mild cough at extubation; Grade 1, multiple, not sustained cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking).</description>
        <time_frame>from the time of eye opening to 5 min after extubation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Coughing Grade</title>
            <description>The coughing incidence and severity will be measured at extubation. Especially from the time of eye opening to 5 min after extubation. The coughing grade was assessed by the following cough grading system: Grade 0, no cough or single, mild cough at extubation; Grade 1, multiple, not sustained cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="0.9"/>
                  <measurement group_id="O2" value="1.4" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergence Time</title>
        <description>The emergence time will be recorded as the time from sevoflurane discontinuation to eye opening on command.</description>
        <time_frame>from sevoflurane discontinuation, up to the time of eye opening (estimated time : from 5 min to 10 min)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Emergence Time</title>
            <description>The emergence time will be recorded as the time from sevoflurane discontinuation to eye opening on command.</description>
            <units>sec</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="492" spread="176"/>
                  <measurement group_id="O2" value="355" spread="151"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 hours</time_frame>
      <desc>prolonged intubation more than 3 hrs, due to changed surgical plan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>prolonged intubation</sub_title>
                <description>1 patient in Dex group was intubated more than 3 hrs due to changed surgical plan.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeongsoo Lee</name_or_title>
      <organization>Yonsei Univ. Health System, Gangnam Severance Hospital</organization>
      <phone>+82-2-2019-6092</phone>
      <email>ration99@yuhs.ac</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
